Prelude Therapeutics announced the pricing of an offering consisting of 18,018,014 shares of voting common stock at $4.44 per share and pre-funded warrants for 2,252,252 shares at $4.4399 each, generating approximately $90.0 million in gross proceeds. The offering is scheduled to close on or about April 21, 2026, subject to customary closing conditions.

The company intends to use the net proceeds primarily for general corporate purposes, including advancing research, preclinical and clinical development of its product candidates, as well as increasing working capital and funding capital expenditures.

RA Capital Management led the offering with participation from Soleus Capital and other healthcare-focused investors. Goldman Sachs & Co. LLC, Evercore ISI and Citizens Capital Markets served as joint book-running managers for the transaction.